• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy.

作者信息

Kim Minhye, Na Ji Min, Lee Gyeong-Won, Lee Seung Jun, Kim Jong Duk, Yang Jung Wook

机构信息

Department of Pathology, Gyeonsang National University Hospital, Jinju, Korea.

Division of Hematology-Oncology, Department of Internal Medicine, Gyeonsang National University Hospital, Gyeongsang National University College of Medicine, Jinju, Korea.

出版信息

J Pathol Transl Med. 2021 Jan;55(1):79-82. doi: 10.4132/jptm.2020.11.02. Epub 2020 Dec 3.

DOI:10.4132/jptm.2020.11.02
PMID:33260286
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7829570/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93e5/7829570/a7c1eb0b9871/jptm-2020-11-02f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93e5/7829570/509d14c5e41b/jptm-2020-11-02f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93e5/7829570/a7c1eb0b9871/jptm-2020-11-02f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93e5/7829570/509d14c5e41b/jptm-2020-11-02f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/93e5/7829570/a7c1eb0b9871/jptm-2020-11-02f2.jpg

相似文献

1
EGFR-mutated pulmonary adenocarcinoma with concurrent PIK3CA mutation, and with acquired RET fusion and EGFR T790M mutation after afatinib therapy.伴有PIK3CA共突变的EGFR突变型肺腺癌，以及在阿法替尼治疗后出现获得性RET融合和EGFR T790M突变。
J Pathol Transl Med. 2021 Jan;55(1):79-82. doi: 10.4132/jptm.2020.11.02. Epub 2020 Dec 3.
2
Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.在第一代或第二代EGFR TKI治疗中出现进展的EGFR突变型NSCLC患者中，RET重排与激活的EGFR突变共存的情况。
Lung Cancer. 2015 Sep;89(3):357-9. doi: 10.1016/j.lungcan.2015.06.021. Epub 2015 Jun 29.
3
Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor-naïve patients with non-small cell lung cancer harboring mutations.在未接受过表皮生长因子受体（EGFR）酪氨酸激酶抑制剂治疗、携带特定突变的非小细胞肺癌患者中，阿法替尼治疗期间获得T790M耐药突变。
Oncotarget. 2017 Jul 12;8(40):68123-68130. doi: 10.18632/oncotarget.19243. eCollection 2017 Sep 15.
4
Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.阿法替尼可增加具有获得性表皮生长因子受体（EGFR）T790M突变的非小细胞肺癌细胞对辐射的敏感性。
Oncotarget. 2015 Mar 20;6(8):5832-45. doi: 10.18632/oncotarget.3332.
5
Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo.阿法替尼、西妥昔单抗和贝伐单抗三联疗法可在体内使携带EGFR T790M的肺癌细胞深度缓解。
Mol Oncol. 2017 Jun;11(6):670-681. doi: 10.1002/1878-0261.12063. Epub 2017 May 2.
6
Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.在携带表皮生长因子受体（EGFR）突变的肺腺癌中发现的不同的阿法替尼耐药机制。
Mol Cancer Res. 2017 Jul;15(7):915-928. doi: 10.1158/1541-7786.MCR-16-0482. Epub 2017 Mar 13.
7
Characterization of EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afatinib in Lung Cancer.表皮生长因子受体（EGFR）T790M、L792F和C797S突变作为肺癌中阿法替尼获得性耐药机制的特征分析
Mol Cancer Ther. 2017 Feb;16(2):357-364. doi: 10.1158/1535-7163.MCT-16-0407. Epub 2016 Dec 2.
8
Inhibition of IGF1R signaling abrogates resistance to afatinib (BIBW2992) in EGFR T790M mutant lung cancer cells.抑制IGF1R信号传导可消除EGFR T790M突变肺癌细胞对阿法替尼（BIBW2992）的耐药性。
Mol Carcinog. 2016 May;55(5):991-1001. doi: 10.1002/mc.22342. Epub 2015 Jun 4.
9
An EGFR-mutated Lung Adenocarcinoma Undergoing Squamous Cell Carcinoma Transformation Exhibited a Durable Response to Afatinib.一例发生鳞状细胞癌转化的表皮生长因子受体（EGFR）突变型肺腺癌对阿法替尼表现出持久反应。
Intern Med. 2018 Dec 1;57(23):3429-3432. doi: 10.2169/internalmedicine.0999-18. Epub 2018 Aug 10.
10
A phase II trial of EGFR-TKI readministration with afatinib in advanced non-small-cell lung cancer harboring a sensitive non-T790M EGFR mutation: Okayama Lung Cancer Study Group trial 1403.一项在携带敏感非 T790M EGFR 突变的晚期非小细胞肺癌患者中重新使用阿法替尼的 EGFR-TKI Ⅱ期临床试验：冈山大肺癌研究组试验 1403。
Cancer Chemother Pharmacol. 2018 Dec;82(6):1031-1038. doi: 10.1007/s00280-018-3694-5. Epub 2018 Oct 1.

引用本文的文献

1
Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.病例报告：在一名患有ANK3-RET融合阳性非小细胞肺癌的年轻白种人中，首次证明了调整剂量的塞尔帕替尼具有显著疗效。
Front Oncol. 2024 Feb 7;14:1307458. doi: 10.3389/fonc.2024.1307458. eCollection 2024.
2
RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.RET原癌基因——并非癌症治疗中一个显而易见的起点。
Cancers (Basel). 2022 Oct 27;14(21):5298. doi: 10.3390/cancers14215298.
3
Clinicopathologic characteristics and diagnostic methods of rearrangement in Chinese non-small cell lung cancer patients.

本文引用的文献

1
Receptor Tyrosine Kinase Fusions as an Actionable Resistance Mechanism to EGFR TKIs in EGFR-Mutant Non-Small-Cell Lung Cancer.受体酪氨酸激酶融合作为表皮生长因子受体酪氨酸激酶抑制剂（EGFR-TKIs）在EGFR突变的非小细胞肺癌中可利用的耐药机制
Trends Cancer. 2019 Nov;5(11):677-692. doi: 10.1016/j.trecan.2019.09.008. Epub 2019 Oct 29.
2
Landscape of Acquired Resistance to Osimertinib in -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired Fusion.奥希替尼获得性耐药的非小细胞肺癌的全景及奥希替尼联合 BLU-667 对获得性融合的 EGFR 和 RET 联合抑制的临床验证
Cancer Discov. 2018 Dec;8(12):1529-1539. doi: 10.1158/2159-8290.CD-18-1022. Epub 2018 Sep 26.
3
中国非小细胞肺癌患者重排的临床病理特征及诊断方法
Transl Lung Cancer Res. 2022 Apr;11(4):617-631. doi: 10.21037/tlcr-22-202.
Impact of Concurrent PIK3CA Mutations on Response to EGFR Tyrosine Kinase Inhibition in EGFR-Mutant Lung Cancers and on Prognosis in Oncogene-Driven Lung Adenocarcinomas.
PIK3CA 基因突变与 EGFR 突变型肺癌对 EGFR 酪氨酸激酶抑制剂的反应及对驱动基因肺腺癌预后的影响。
J Thorac Oncol. 2015 Dec;10(12):1713-9. doi: 10.1097/JTO.0000000000000671.
4
PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies.非小细胞肺癌（NSCLC）中的PIK3CA突变：遗传异质性、预后影响及既往恶性肿瘤的发生率
Oncotarget. 2015 Jan 20;6(2):1315-26. doi: 10.18632/oncotarget.2834.
5
Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers.鉴定从不吸烟者肺腺癌中 EGFR/KRAS/ALK 阴性的体细胞突变。
Genome Med. 2014 Feb 27;6(2):18. doi: 10.1186/gm535. eCollection 2014.
6
PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup.PIK3CA突变在非小细胞肺癌中常与EGFR/KRAS突变共存，并提示在EGFR/KRAS野生型亚组中预后较差。
PLoS One. 2014 Feb 12;9(2):e88291. doi: 10.1371/journal.pone.0088291. eCollection 2014.